vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative orally administered small molecule therapies aimed at addressing significant unmet medical needs. The company's robust pipeline includes treatments targeting central nervous system disorders and metabolic diseases, reflecting its commitment to advancing healthcare solutions. With a seasoned management team and strategic partnerships, vTv Therapeutics is positioned to deliver transformative therapies to the market, enhancing patient outcomes and driving shareholder value.